PriceTargets.com logo

NASDAQ:BCDA - BioCardia Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.25
  • Forecasted Upside: 120.24 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.20 As of 04/13/2021 01:00 AM ET
▲ +0.19 (4.74%)
1 month | 3 months | 12 months
Get New BioCardia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCDA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$9.25
▲ +120.24% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for BioCardia in the last 3 months. The average price target is $9.25, with a high forecast of $11.50 and a low forecast of $7.00. The average price target represents a 120.24% upside from the last price of $4.20.
Buy
The current consensus among 2 polled investment analysts is to buy stock in BioCardia.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/18/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/16/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/21/2020Alliance Global PartnersInitiated CoverageBuy$11.50High
i
8/14/2020Maxim GroupInitiated CoverageBuy$7.00Medium
i
Rating by Jason McCarthy at Maxim Group
5/1/2020Maxim GroupInitiated CoverageBuy$9.00Low
i
Rating by Jason McCarthy at Maxim Group
4/1/2020Maxim GroupReiterated RatingBuy$9.00High
i
Rating by Jason McCarthy at Maxim Group
11/26/2019Brookline Capital ManagementReiterated RatingBuyLow
i
Rating by K. Raja at Brookline Capital Management
11/26/2019Brookline Capital ManagementInitiated CoverageBuy$22.00Low
i
10/10/2019Maxim GroupInitiated CoverageBuy$9.00 ➝ $9.00High
i
9/17/2019Dawson JamesInitiated CoverageBuy$24.00Low
i
Rating by Jason Kolbert at Dawson James
9/17/2019Dawson JamesReiterated RatingBuyMedium
i
Rating by J. Kolbert at Dawson James
(Data available from 4/14/2016 forward)
BioCardia logo
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
Read More

Today's Range

Now: $4.20
$4.02
$4.25

50 Day Range

MA: $4.10
$3.42
$4.61

52 Week Range

Now: $4.20
$1.91
$8.60

Volume

120,402 shs

Average Volume

299,251 shs

Market Capitalization

$68.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.98

Frequently Asked Questions

What sell-side analysts currently cover shares of BioCardia?

The following equities research analysts have issued stock ratings on BioCardia in the last year: Alliance Global Partners, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for BCDA.

What is the current price target for BioCardia?

2 Wall Street analysts have set twelve-month price targets for BioCardia in the last year. Their average twelve-month price target is $9.25, suggesting a possible upside of 120.2%. Alliance Global Partners has the highest price target set, predicting BCDA will reach $11.50 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $7.00 for BioCardia in the next year.
View the latest price targets for BCDA.

What is the current consensus analyst rating for BioCardia?

BioCardia currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCDA will outperform the market and that investors should add to their positions of BioCardia.
View the latest ratings for BCDA.

What other companies compete with BioCardia?

Other companies that are similar to BioCardia include CASI Pharmaceuticals, Cabaletta Bio, Protalix BioTherapeutics, ADMA Biologics, LogicBio Therapeutics, Protara Therapeutics, Gamida Cell, Genfit, Axcella Health, Voyager Therapeutics, Applied Genetic Technologies, INmune Bio, Fennec Pharmaceuticals, Checkmate Pharmaceuticals and Champions Oncology.

How do I contact BioCardia's investor relations team?

BioCardia's physical mailing address is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. The company's listed phone number is 650-226-0120 and its investor relations email address is [email protected] The official website for BioCardia is www.biocardia.com.